よむ、つかう、まなぶ。
会議資料 (177 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000198856_00046.html |
| 出典情報 | 医療上の必要性の高い未承認薬・適応外薬検討会議（第68回 5／25）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
要望番号；III➀-73
109/l and platelets > 100 × 109/l is accomplished.
This usually happens at around 18 to 21 days after the cycle except between
CYVE cycles in positive CNS patients, which is around the 28th day.
- The Rituximab dose of day -2 could start as soon as granulocytes ≥ 0.5 ×
109/l without infection.
- The second cycle usually starts around 18 days after the first one; it is
recommended to be no less than 16 days or more than 21 days later. If the
clinical condition does not allow starting treatment before 21 days, a
“waiting COP” or at least a rituximab interphase would be an option to avoid
treatment discontinuation.
Rituximab window R for high risk patients (prior to each course except
the COP pre-phase)
-
Rituximab
375
mg/m2/d
IV
on
days
-2
and
1
for
R-COPADM/R-COPADM2 and on day 1 for R-CYM and R-CYVE.
ガイドラインの根拠
① 英国 Children's Cancer and Leukaemia Group の診療ガイドライン
論文
•
Goldman S, Smith L, Anderson JR, et al. Rituximab and FAB/LMB 96
chemotherapy in children with Stage III/IV B-cell non-Hodgkin
lymphoma: a Children's Oncology Group report. Leukemia 2013; 27(5):
1174-1177.9)
•
Minard-Colin V, Aupérin A, Pillon M, et al. Rituximab for High-Risk,
Mature B-Cell Non-Hodgkin's Lymphoma in Children. N Engl J Med
2020; 382(23): 2207-2219.1)
②
EICNHL 及び国際 BFM による、小児及び思春期の NHL に関する
欧州標準臨床診療レコメンデーション
[40] Minard-Colin V, Auperin A, Pillon M, et al. Results of the randomized
Intergroup trial Inter-B-NHL Ritux 2010 for children and adolescents
with high-risk B-cell non-Hodgkin lymphoma (B-NHL) and mature
acute leukemia (B-AL): Evaluation of rituximab (R) efficacy in addition
to standard LMB chemotherapy (CT) regimen. Journal of Clinical
Oncology 2016; 34(15 suppl): 10507-10507. (Meeting Abstract: 2016
ASCO Annual Meeting I)18)
備考
３）独国
ガイドライン名
英国のガイドライン②と同様
効能・効果
41
177/370
109/l and platelets > 100 × 109/l is accomplished.
This usually happens at around 18 to 21 days after the cycle except between
CYVE cycles in positive CNS patients, which is around the 28th day.
- The Rituximab dose of day -2 could start as soon as granulocytes ≥ 0.5 ×
109/l without infection.
- The second cycle usually starts around 18 days after the first one; it is
recommended to be no less than 16 days or more than 21 days later. If the
clinical condition does not allow starting treatment before 21 days, a
“waiting COP” or at least a rituximab interphase would be an option to avoid
treatment discontinuation.
Rituximab window R for high risk patients (prior to each course except
the COP pre-phase)
-
Rituximab
375
mg/m2/d
IV
on
days
-2
and
1
for
R-COPADM/R-COPADM2 and on day 1 for R-CYM and R-CYVE.
ガイドラインの根拠
① 英国 Children's Cancer and Leukaemia Group の診療ガイドライン
論文
•
Goldman S, Smith L, Anderson JR, et al. Rituximab and FAB/LMB 96
chemotherapy in children with Stage III/IV B-cell non-Hodgkin
lymphoma: a Children's Oncology Group report. Leukemia 2013; 27(5):
1174-1177.9)
•
Minard-Colin V, Aupérin A, Pillon M, et al. Rituximab for High-Risk,
Mature B-Cell Non-Hodgkin's Lymphoma in Children. N Engl J Med
2020; 382(23): 2207-2219.1)
②
EICNHL 及び国際 BFM による、小児及び思春期の NHL に関する
欧州標準臨床診療レコメンデーション
[40] Minard-Colin V, Auperin A, Pillon M, et al. Results of the randomized
Intergroup trial Inter-B-NHL Ritux 2010 for children and adolescents
with high-risk B-cell non-Hodgkin lymphoma (B-NHL) and mature
acute leukemia (B-AL): Evaluation of rituximab (R) efficacy in addition
to standard LMB chemotherapy (CT) regimen. Journal of Clinical
Oncology 2016; 34(15 suppl): 10507-10507. (Meeting Abstract: 2016
ASCO Annual Meeting I)18)
備考
３）独国
ガイドライン名
英国のガイドライン②と同様
効能・効果
41
177/370